Entrada Therapeutics, Inc. (TRDA) Dividend History

Company News

• Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

  Entrada Therapeutics awarded $50,000 grants to Jett Foundation and Parent Project aps to support Duchenne muscular dystrophy community initiatives focused on equity, accessibility, and inclusion in the U.S. and Italy.

  GlobeNewswire Inc.
• Entrada (TRDA) Q2 Revenue Drops 98%

  Entrada Therapeutics reported a significant revenue drop and wider-than-expected loss in Q2 2025, primarily due to the conclusion of its partnership with Vertex Pharmaceuticals. Despite financial challenges, the company continues advancing its clinical pipeline for neuromuscular and genetic disease therapies.

  The Motley Fool

  Featured Companies: VRTX
• Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

  Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.

  Zacks Investment Research

  Featured Companies: EXAS LLY NKTR
• Insiders Buying America's Car-Mart And 2 Other Stocks

  Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. HCI Group The Trade: HCI Group Inc (NYSE: HCI) CEO Paresh Patel acquired a total of 1,000 shares an average ...

  Benzinga

  Featured Companies: CRMT HCI